 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
31 News |  |
- | Cervidil (dinoprostone) / Ferring
Journal: Determination of Prostaglandins (Carboprost, Cloprostenol, Dinoprost, Dinoprostone, Misoprostol, Sulprostone) by UHPLC-MS/MS in Toxicological Investigations. (Pubmed Central) - Oct 27, 2023
Misoprostol and diclofenac dose per sample were as follows: 608.8 ng (sample 1), 708.4 ng (sample 2), 618.8 ng (sample 3) and 67.7 mg (sample 1), 65.3 mg (sample 2) 67.3 mg (sample 3), respectively. A simple, precise and reliable method can be applied for routine examinations in terms of clinical and forensic toxicology examinations as well as in quality control of drugs for pharmaceutical purposes (original drugs and counterfeit medications).
- | Journal: Nonopioid drugs for pain. (Pubmed Central) - Mar 3, 2022
A simple, precise and reliable method can be applied for routine examinations in terms of clinical and forensic toxicology examinations as well as in quality control of drugs for pharmaceutical purposes (original drugs and counterfeit medications). No abstract available
- || diclofenac/misoprostol / Generic mfg.
Clinical, Journal: Oxytocin and Misoprostol With Diclofenac in the Preparation for Magnetic Resonance-Guided High-Intensity Ultrasound Treatment of Symptomatic Uterine Fibroids: A Prospective Cohort Study. (Pubmed Central) - Sep 19, 2021
The administration of vasoconstrictor drugs (oxytocin and misoprostol/diclofenac) to support MR-HIFU in UF treatment is a new issue that may improve the total effectiveness of this method. Randomized controlled trials are necessary to estimate the real effect of vasoconstrictors on MR-HIFU.
- | diclofenac/misoprostol / Generic mfg.
Journal: Magnetic Resonance-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids-Efficiency Assessment with the Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging and the Potential Role of the Administration of Uterotonic Drugs. (Pubmed Central) - May 1, 2021
Our results suggest that DCE-MRI has the potential to assess treatment outcomes among patients with UFs, and patients with UFs that present with a washout curve may benefit from the use of uterotonic drugs. More studies are required to draw final conclusions.
- || diclofenac/misoprostol / Generic mfg.
میخواین درد پریود رو شبیه سازی کنید؟ یه مسکن حاوی میزوپروستول بخورید. مثل آرتروتک که علاوه بر دیکلوفناک، ۲۰۰ میکروگرم میزوپروستول برای محافظت از معده داره. تمام دردهای پریود و تهوع و استفراغش رو در جا تجربه می کنید! @pfizer #arthrotec (Twitter) - Nov 3, 2020
- || Arthrotec (diclofenac & misoprostol) / Pfizer
Clinical, Journal: Evaluation of prescription pattern of analgesic use among ambulatory elderly in South-Western Nigeria. (Pubmed Central) - Sep 13, 2020
Majority of hypertensive patients were on NSAIDs. This calls for prompt awareness of rational analgesic use among the elderly to improve management and their survival.
- | Omeprazole RBX (omeprazole) / Generic mfg., Arthrotec (diclofenac & misoprostol) / Pfizer
Journal: CHARACTERISTICS OF THE PROTECTIVE EFFECTS OF QUERTZETIN AND ITS WATER-SOLUBLE FORM CORVITIN IN THE MODEL OF DICLOFENAC-INDUCED GASTROPATHY (Pubmed Central) - Jan 24, 2020
Preventive administration of rats before diclofenac corvitin or quercetin was similar to reference drugs inhibiting the ulcerogenic effect of this NSAID, indicating a probable decrease in the number of destructions per gastric mucosa respectively at 78% and 76% against 82% under the action of omeprazole. Preventive administration of quercetin (corvitin) before diclofenac to the same extent as omeprazole promotes weaken the ulcerogenicity of this NSAID.
- | Clinical, Journal: Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. (Pubmed Central) - Apr 17, 2019
The relative risk estimates of AMI differed slightly between 28 individual NSAIDs. The relative risk was highest for ketorolac and was correlated with COX-2 potency, but not restricted to coxibs.
- | Trial completion: Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis) (clinicaltrials.gov) - Jun 15, 2017
P=N/A, N=240, Completed, Sponsor: University of Pittsburgh
The relative risk was highest for ketorolac and was correlated with COX-2 potency, but not restricted to coxibs. Active, not recruiting --> Completed
- Trial primary completion date: Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis) (clinicaltrials.gov) - May 13, 2016
P=N/A, N=240, Active, not recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Jun 2016
- Enrollment closed, Enrollment change: Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis) (clinicaltrials.gov) - Nov 26, 2015
P=N/A, N=240, Active, not recruiting, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Active, not recruiting | N=180 --> 240
- Enrollment open: Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis) (clinicaltrials.gov) - Oct 21, 2013
P=N/A, N=180, Recruiting, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting | N=180 --> 240 Not yet recruiting --> Recruiting